Condition
Hemopathy
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Unknown2
Completed1
Recruiting1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06369389RecruitingPrimary
Real-life Management of Patients Eligible for CAR-T Cell Therapy
NCT02065297Completed
Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
NCT02751112Not ApplicableTerminatedPrimary
Evaluation of a Kit for the Prediction of the Risk of Graft Versus Host Disease
NCT02260739Not ApplicableUnknownPrimary
Sequential Analysis in Patients With an Hemopathy
NCT03102905Unknown
Prevalence of Replication of Human Herpes Virus 6 (HHV6) in Blood and Skin During Exanthemia, in Patients With Hemopathy. Is There a Correlation With the Etiology of the Exanthema?
Showing all 5 trials